These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 16716134)

  • 21. Rasburicase for the management of tumor lysis syndrome in neonates.
    McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS
    Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
    Savva DA; Herrera N; Rohatgi R
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
    Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
    Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
    Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
    Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
    Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G; Giordano M; Malaguarnera M
    Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis.
    Yu X; Liu L; Nie X; Li J; Zhang J; Zhao L; Wang X
    J Clin Pharm Ther; 2017 Feb; 42(1):18-26. PubMed ID: 27888526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
    Bessmertny O; Robitaille LM; Cairo MS
    Curr Pharm Des; 2005; 11(32):4177-85. PubMed ID: 16375739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
    Trifilio S; Gordon L; Singhal S; Tallman M; Evens A; Rashid K; Fishman M; Masino K; Pi J; Mehta J
    Bone Marrow Transplant; 2006 Jun; 37(11):997-1001. PubMed ID: 16708061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices.
    Gilmore S; Carroll M; Koselke E; Hough S
    J Oncol Pharm Pract; 2024 Jul; 30(5):867-872. PubMed ID: 37563922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rasburicase in the prevention and treatment of tumour lysis syndrome.
    Mayne N; Keady S; Thacker M
    Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.
    Eaddy M; Seal B; Tangirala K; Davies EH; O'Day K
    Appl Health Econ Health Policy; 2012 Nov; 10(6):431-40. PubMed ID: 23013428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
    Eng S; Lee CS; Ahn S; Sharma A
    J Oncol Pharm Pract; 2020 Mar; 26(2):338-344. PubMed ID: 31088218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
    Abousaud MI; Rush MC; Rockey M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1165-1171. PubMed ID: 32727320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
    Bertrand Y; Mechinaud F; Brethon B; Mialou V; Auvrignon A; Nelken B; Notz-Carrère A; Plantaz D; Patte C; Urbieta M; Baruchel A; Leverger G;
    J Pediatr Hematol Oncol; 2008 Apr; 30(4):267-71. PubMed ID: 18391694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 40. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006945. PubMed ID: 28272834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.